Breast Implant-Associated Tumors
Brustimplantatassoziierte Tumoren

Authors
Uwe von Fritschen1, Thomas Kremer2, Lukas Prantl3, Alba Fricke1,4

Affiliations
1 Department of Plastic- and Aesthetic Surgery, Helios Klinik Emil von Behring, Berlin, Germany
2 Klinik für Plastische und Handchirurgie mit Schwerbrandverletztenzentrum, Klinikum St. Georg, Dresden, Germany
3 Abteilung für Plastische-, Hand- und Rekonstruktive Chirurgie, Universität Regensburg, Regensburg, Germany
4 Department of Plastic and Hand Surgery, University of Freiburg Medical Centre, Medical Faculty of the University of Freiburg, Freiburg, Germany

Key words
breast implant, lymphoma, BIA-SCC, immunostimulation, textured implants, squamous cell carcinoma, implant-associated tumors, BIA-ALCL

Schlüsselwörter
Brustimplantat, Lymphom, BIA-SCC, Immunstimulation, texturierte Implantate, Plattenepithelkarzinom, implantassozierte Tumoren, BIA-ALCL

received 6.2.2023
accepted after revision 13.4.2023

ABSTRACT
In addition to anaplastic large T-cell lymphomas (BIA-ALCL), other implant-related tumors have been described for some years. Squamous cell carcinoma (SSC) and B-cell lymphomas occurred in very rare cases. The unexplained pathogenesis as well as the unclear individual risk profile is an ongoing source of uncertainty for patients and physicians. The pathogenesis of the tumors is still largely not understood. While BIA-ALCL occurs more frequently with textured breast implants, other tumors were also observed with smooth implants and at other implant sites. Multiple potential mechanisms are discussed. It is suspected that the etiology of a chronic inflammatory response and subsequently immunostimulation is multifactorial and appears to play a key role in the malignant transformation. Since there are currently no sufficiently valid data for a specific risk assessment, this must be done with caution. This article presents the incidence, pathogenesis, as well as the level of evidence according to the current state of knowledge, and evaluates and discusses the current literature.

ZUSAMMENFASSUNG
Introduction
By far the most common tumor of these forms is breast implant-associated anaplastic large cell lymphoma (BIA-ALCL), a very rare subtype of non-Hodgkin's lymphoma. Unlike primary, sporadic ALCL of the breast, BIA-ALCL is not a tumor of the breast tissue. It occurs predominantly inside the implant capsule after textured silicone implants have been implanted.

It is difficult to assess the exact number of cases worldwide, as the unstructured reports are partly incomplete or redundant in various databases [1]. There is also often a lack of information on implant history, clinical course, and histology. In addition to unreliable data on incidence, there are also no reliable trade sales or implant data available. When comparing countries, there are significant differences between the reported cases, the reasons for which have not yet been clarified (cf. ▶Table 1) [2].

Among the reported cases, there was a strikingly high number of macrotextured implants at the time of explantation. Despite unsatisfactory data, all macrotextured implants were removed from the market in April 2019. Microtextured implants are affected much less frequently; smooth implants, as far as we know, are not affected at all.

The passive vigilance systems currently in use are not sufficient to gain a better understanding of the disease, as well as to identify future implant-based problems early on. Instead, mandatory data collection with networking to evaluate all register data is required on an international level [3]. Germany is currently a global pioneer in this regard with the Implant Register Act [4].

Epidemiology of BIA-ALCL
Sporadic ALCL of the breast is a very rare disease with an incidence of approximately 0.037 per 1 million women. In addition, these are usually of B-cell origin. T-cell lymphomas affect less than 6% [5, 6]. By comparison, the occurrence of implant-associated ALCL is still very rare, but it is more common than would be expected in the sporadic forms [7, 8]. Retrospective studies on this are subject to limitations. This form has only been listed as a distinct entity since 2013. To date, both are difficult to distinguish, even by means of immunohistochemical or genetic analysis. Due to better discrimination techniques, the preliminary classification has been abandoned [9, 10, 11].

▶Table 1 Registered BIA-ALCL cases in the PROFILE database.

<table>
<thead>
<tr>
<th>Country</th>
<th>Population (millions)</th>
<th>Cases</th>
<th>Deceased</th>
</tr>
</thead>
<tbody>
<tr>
<td>Argentina</td>
<td>45.8</td>
<td>17</td>
<td>0</td>
</tr>
<tr>
<td>Australia</td>
<td>25.7</td>
<td>112</td>
<td>4</td>
</tr>
<tr>
<td>Austria</td>
<td>9</td>
<td>6</td>
<td>0</td>
</tr>
<tr>
<td>Belgium/Luxembourg</td>
<td>12.2</td>
<td>26</td>
<td>0</td>
</tr>
<tr>
<td>Brazil</td>
<td>214</td>
<td>31</td>
<td>1</td>
</tr>
<tr>
<td>Canada</td>
<td>28.3</td>
<td>38</td>
<td>1</td>
</tr>
<tr>
<td>Chile</td>
<td>19.6</td>
<td>2</td>
<td>0</td>
</tr>
<tr>
<td>China</td>
<td>1412</td>
<td>1</td>
<td>0</td>
</tr>
<tr>
<td>Denmark</td>
<td>5.9</td>
<td>13</td>
<td>0</td>
</tr>
<tr>
<td>France</td>
<td>67.7</td>
<td>99</td>
<td>4</td>
</tr>
<tr>
<td>Germany</td>
<td>84</td>
<td>46</td>
<td>0</td>
</tr>
<tr>
<td>Greece</td>
<td>10.6</td>
<td>1</td>
<td>0</td>
</tr>
<tr>
<td>Hungary</td>
<td>9.7</td>
<td>1</td>
<td>0</td>
</tr>
<tr>
<td>Israel</td>
<td>9.4</td>
<td>9</td>
<td>0</td>
</tr>
<tr>
<td>Italy</td>
<td>59.1</td>
<td>73</td>
<td>2</td>
</tr>
<tr>
<td>Japan</td>
<td>125.7</td>
<td>4</td>
<td>0</td>
</tr>
<tr>
<td>Mexico</td>
<td>126.7</td>
<td>14</td>
<td>0</td>
</tr>
<tr>
<td>Netherlands</td>
<td>17.5</td>
<td>70</td>
<td>2</td>
</tr>
<tr>
<td>New Zealand</td>
<td>5.1</td>
<td>20</td>
<td>1</td>
</tr>
<tr>
<td>Norway</td>
<td>5.4</td>
<td>13</td>
<td>0</td>
</tr>
<tr>
<td>Poland</td>
<td>37.7</td>
<td>10</td>
<td>0</td>
</tr>
<tr>
<td>Russia</td>
<td>144.7</td>
<td>8</td>
<td>0</td>
</tr>
<tr>
<td>Spain</td>
<td>47.6</td>
<td>74</td>
<td>3</td>
</tr>
<tr>
<td>Switzerland</td>
<td>8.7</td>
<td>11</td>
<td>0</td>
</tr>
<tr>
<td>Sweden</td>
<td>10.6</td>
<td>8</td>
<td>2</td>
</tr>
<tr>
<td>United Kingdom</td>
<td>67.5</td>
<td>78</td>
<td>1</td>
</tr>
<tr>
<td>United States</td>
<td>332</td>
<td>402</td>
<td>8</td>
</tr>
<tr>
<td>Other</td>
<td>60</td>
<td>2</td>
<td></td>
</tr>
<tr>
<td>Total</td>
<td>1233</td>
<td>31</td>
<td></td>
</tr>
</tbody>
</table>

Modified according to https://www.plasticsurgery.org/documents/Health-Policy/ALCL/PROFILE-Data-Summaries_Sept22.pdf
The cases recorded here do not correspond to the reports submitted to the FDA [1].
The number of procedures with breast implants performed worldwide is unknown. According to conservative estimates, there are approximately 35 million breast implant patients. According to the global survey of the ISAPS (International Society of Aesthetic Plastic Surgery), approximately 1.68 million implant procedures are performed annually [12].

A total of 1130 cases were reported to the Food and Drug Administration (FDA) up to April 2022, including 59 deaths [13]. Canada has reported 64 confirmed cases and 25 suspected cases to date; of these, 3 were deaths (as of: 6 April 2022) [14]. Up to September 2022, Australian authorities received reports of 112 cases. In the EU, 398 cases were reported to the Task Force on BIA-ALCL, which consists of regulatory authorities; 345 of these cases could be confirmed [15]. In Germany, there is an obligation to report this disease. Currently, 46 BIA-ALCL cases have been registered with the Federal Institute of Drugs and Medical Devices (BfArM), with no deaths reported (update from 06.03.2023) [16].

Reports in the EU are very low compared to Australia and New Zealand. This is also reflected in the small number of epidemiological studies. Overall, data on the lifetime risk vary between 1.65 and 35 cases per 100 000 women with implants [5, 17, 18, 19, 20]. In estimating the number of implants required to induce BIA-ALCL, Cordeiro et al. reported 10 individual cases from a cohort of 3546 women. This corresponds to a cumulative incidence of 1 : 355 patients [19]. In contrast, Doren et al. assume an absolute cumulative risk of 29/1 million women up to 50 years of age and an increase to 82/1 million at 75 years of age. The estimated rate ranges from 1 : 6600 to 1 : 53300, depending on the implant type used [17]. For Australia and New Zealand, the risk is reported at 1 : 2832 for polyurethane, 1 : 3345 for biocell (BIOCELL, Allergan, Dublin, Ireland), and 1 : 86029 for siltex surfaces (Siltex, Mentor, Germany) [21].

Because no reliable trade sales or implant data are available, all authors took different approaches. For example, De Boer et al. extrapolated the prevalence of implants from 3000 randomly selected X-ray examinations and used this to determine the prevalence of female implant wearers in the Netherlands at 3.3 %. The information on the implant types results from the manufacturer’s information on the nationwide sales figures, but not on the products actually used [5].

Incomplete data on implant history also prevent a reliable evaluation. In most countries, textured implants are predominantly used. It is therefore understandable why reports predominantly concern this type of surface. In contrast to this, almost exclusively smooth implants are used in the USA. Nevertheless, of the 1130 cases reported by the FDA, 798 had textured implants at the time of explantation, and only 37 had smooth surfaces (cf. Table 2).

Therefore, information on incidence, especially for evaluating specific implants, must be assessed with caution. Considering these data, a causal relationship with macrotextured implants must be assumed. Due to the lack of a reliable denominator, there has been no way to calculate the risk for other implant types. The available data indicate that patients with breast implants have a low absolute but high relative risk of developing BIA-ALCL.

However, in this context, it must be noted that the vast majority of diseases occurred with macrotextured implants. These implants have now been taken off the market, so a prospective risk assessment is almost impossible. Moreover, it is unclear whether we are only at the beginning of a problem due to the high rate of use of these products, and how surgeons should proceed with the capsule of this implant if revision procedures are required.

### Causes

The pathogenesis of the tumor has not yet been clarified. Various hypotheses are being discussed that indicate a multifactorial etiology. In any case, immunostimulation by a subclinical chronic inflammatory response appears to play a relevant role. It is suspected that this persistent stimulation of T-cells triggers their deregulated clonal expansion. Triggers could be implant-related, i.e., an inflammatory response due to the implant sheath itself, abrasion of silicone particles or allergic hypersensitivity, but also procedure-related, e.g., bacterial contamination with certain pathogens and the formation of a biofilm. In addition, an altered immune response could play a role due to the high rate of use of these products, and how surgeons should proceed with the capsule of this implant if revision procedures are required.

Because of the uncertain denominator, there is currently insufficient scientific evidence for any of these hypotheses.

It is also being discussed whether, at least in some cases, activated T lymphocytes are merely a lymphoproliferative reaction, as seen in other, mostly viral inflammatory processes, without necessarily resulting in malignant transformation. This would be a potential explanation for the relatively small number of ALCL cases requiring treatment in the past [15, 24, 25].

---

### Table 2

<table>
<thead>
<tr>
<th>Data on surface texture</th>
<th>n = 1130</th>
<th>Of which:</th>
</tr>
</thead>
<tbody>
<tr>
<td>No data</td>
<td>295 (26%)</td>
<td>8</td>
</tr>
<tr>
<td>Textured</td>
<td>798 (71%)</td>
<td>10</td>
</tr>
<tr>
<td>Smooth</td>
<td>37 (3%)</td>
<td>18</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>One smooth implant and no known history of textured implant</td>
</tr>
</tbody>
</table>

© 2023. The Author(s).
Implants

BIA-ALCL do not only occur with breast implants, but have also been described with orthopedic materials, dental implants, after bariatric procedures, and when liquid silicone fillers are used. However, this only affects a few individual cases, also with other types of lymphoma. Therefore, the causal relationship must be interpreted very cautiously at this time. In any case, none of these implants have an accumulation like we see with breast implants.

Implanted foreign bodies always trigger an inflammatory reaction and encapsulation. A complex wound healing cascade leads to leukocyte stimulation and differentiation. There is no knowledge to date as to which specific aspects, e.g., of a textured surface, change this course compared to other implant surfaces, and leads to malignant degeneration. However, it is postulated that textured implant surfaces may be more prone to a biofilm forming compared to smooth surfaces; in addition, the contact surface and area of continuous friction between the implant and the implant capsule, as well as the number of silicone particles released, are larger, which could increase the chronic inflammatory response [15, 26, 27, 28].

It is also unclear whether a different texture but equally “high” surface due to different manufacturing processes would have any effect. Examples include the salt-loss technique, in which salt crystals are washed off the surface during manufacturing, leaving sharply edged indentations. Gas diffusion at the time of vulcanization leads to a smaller depth and comparatively rounder pores, which are reduced again during imprint stamping. Finally, polyurethane foam is produced using an entirely different method. Yet many of these surfaces are classified in the same way.

Although it is not possible to conclusively assess the influence of the surface, the incidence varies considerably with different surfaces. Although implants are generally referred to as macro, micro, and nanotextured in comparison to smooth implants, there is currently no generally accepted classification. Therefore, surfaces may be assessed and presented differently by the manufacturers. Polyurethane surfaces are classified as macrotexured, but their foam-like structure makes it difficult to classify them with the given parameters. The most widely used is ISO 14607:2018, which classifies surfaces according to average roughness. This classification is merely descriptive and has not been clinically validated. Measurement technique and production deviations also limit the usefulness. The particular features mentioned above are also not addressed. There are currently approaches to integrate clinical aspects [12].

Focusing on the surface structure alone has not explained the different behaviors so far. Implants with the same surface classification should have a comparable incidence of BIA-ALCL.

Bacterial contamination

Despite the utmost care and efforts to maintain a sterile working environment, contamination with pathogens cannot always be avoided. Late contamination can occur by hematogenous pathways.

A working group in Australia found an increase of specific pathogens in the capsule of BIA-ALCL patients compared to benign capsule fibrosis. In addition, a higher number of pathogens was detected [26]. The findings have not yet been confirmed by other groups [27]. The clinical relevance remains unclear; at any rate the influence of specific pathogens is now considered unlikely.

The colonization of the implant surface causes a biofilm to form. The subclinical inflammation caused by this could contribute to their malignant transformation due to the resulting chronic stimulation of T-cells over several steps and involving individual immunomodulatory factors [29]. Here, it is suggested that a higher surface relief may also contain a higher bacterial load and thus result in a higher risk for T-cell stimulation [30].

Abrasion of microparticles

The abrasion of silicone particles presumably affects implants with a rough surface in particular. This phenomenon has been known for some time; more recently, it has also been described in the context of the histological work-up of capsules affected by BIA-ALCL [4]. Again, it is suggested here that the immune system is activated through various pathways. A causal link to the formation of a tumor has not yet been established.

If implants are defective, the release of larger particles coincides with an inflammatory reaction to the foreign body, incl. by forming granulomas. Whether this is also the case for microparticles cannot be proven in the current literature. The macrophages activated by this process can express cytokines that stimulate a proliferation of T-cells. It is known that they are also transported to local lymph nodes [6]. The clinical relevance has not yet been clarified.

Genetic predisposition

A small number of BIA-ALCL reports occurred in patients with a known familial risk of breast carcinoma. The below-average time after implantation was striking [15, 31]. Some studies have also attempted to compare genetic alterations in the original breast tumor with those of BIA-ALCL or to find genetic abnormalities in tumor material in patients without prior breast carcinoma that may play a role in the pathogenesis. A mutation in genes that influence the activity of the JAK/STAT mechanism was found several times. This plays a role in the downregulation of immunological reactions. Thus, a disorder could be responsible for persistent immunostimulation [32]. Currently, genetic factors are considered to have a significant influence on the etiology [22].

Hypoxia

Tissue hypoxia is currently considered one of the most likely factors for the development of BIA-ALCL. During RNA sequencing, a dramatic upregulation of the hypoxia-associated biomarker carbonic anhydrase 9 (CA-9) has been shown in BIA-ALCL tissue compared to non-BIA ALCL tissue [33].

Clinical Presentation and Diagnosis

BIA-ALCL develop inside the implant sheath and can occur either in situ, i.e., limited to a seroma or as an adherent growth on the capsule, or can be infiltrative. In most cases, a large seroma containing tumor cells develops in a short period of time. This occurs
at least one year after implantation, on average after 7 to 10 years, with reconstructive and esthetic implants being affected with relatively equal frequency. Smaller seromas around an implant are often seen and do not require further diagnosis if the clinical presentation and imaging are otherwise unremarkable. Approximately 8–24% of patients have an isolated or concomitant solid tumor. Systemic symptoms, such as a rash and fever, are very rare. The infiltrative stages may show lymph node involvement, regardless of whether a solid tumor is present [34].

Further diagnostics are performed by ultrasound. Sensitivity and specificity for detecting effusions are reported as 84% and 75% respectively, and 46% and 100% respectively for solid tumors [35]. An ultrasound is therefore the appropriate method, especially for screening. According to the consensus guideline, the different lymphatic pathways should be examined for suspicious changes in addition to fluid retention or a mass lesion. If there is any ambiguity, nuclear magnetic resonance (NMR) is recommended. CT examinations play a minor role. A PET-CT is recommended for questions about systemic spread [36, 37].

A diagnosis is made by analyzing the seroma. Here, it is important to obtain sufficient cell material for flow cytometry. At least 50 ml are required. Serial punctures should be avoided as the diluting effect makes diagnosis more difficult. In addition, a bacterial examination should be performed [38]. Solid tumors are biopsied.

If cell morphology shows abnormalities, the immunohistochemistry panel is expanded. This is also done to exclude other malignant or benign processes that may have a similar picture to BIA-ALCL. CD30 and ALK are the most well-known markers, the former being consistently positive and the latter always negative. However, when considered in isolation, they are not conclusive of BIA-ALCL. Other cutaneous or systemic forms of ALCL may also be ALK-negative. CD30 is a nonspecific marker that can also be found on benign activated T- and B-cells, e.g., in connection with viral infections. Even sparse CD30-positive lymphocytes with unremarkable morphology do not require further diagnostic confirmation. The markers must be detected in cells that exhibit the typical cytological properties of an ALCL. Therefore, other markers must also be included, where appropriate [30, 39, 40].

Assessing whether capsular infiltration is present is essential for further treatment and prognosis. After complete en-bloc resection of the capsule, at least 12 biopsies are recommended for this purpose to assess the resection margins [41].

**Treatment of BIA-ALCL**

There are guidelines and recommendations for treatment [34]. Complete surgical resection of the tumor including the implant capsule (en-bloc resection) is the primary treatment and is crucial for prognosis. In the event of incomplete resection or systemic involvement, adjuvant therapy may be required. This has so far been largely based on the treatment of systemic ALCL as there is a lack of disease-specific experience.

Removal of the sentinel lymph node is not recommended; an excisional biopsy should be performed if lymph nodes are abnormal. In up to 4.6% of cases, the tumor occurred bilaterally. It is therefore recommended to also remove a contralateral implant. Immediate reconstruction with a smooth implant is discussed, as well as primary or secondary reconstruction using the patient’s own tissue. To date, there are no standardized, internationally agreed recommendations for this or for follow-up care [34].

**Prognosis**

BIA-ALCL have a very favorable prognosis if detected early on and treated consistently. According to current knowledge, in-situ tumors are treated curatively by capsule resection alone. Spontaneous regression has been described in individual cases [24]. The problem here is that there are still no parameters to identify benign courses [42]. Infiltrative stages that cannot be fully treated with surgery have a less favorable prognosis with a mortality of up to 40% in 2 years [5, 15].

**Other Breast Implant-Associated Tumors**

Viral infections are responsible for 15%–20% of all human tumors [43]. The Epstein-Barr Virus (EBV) also causes B-cell lymphoma, Burkitt lymphoma, and diffuse large B-cell lymphoma. It has also long been known that chronic inflammation can lead to malignant transformation and squamous cell carcinoma. Marjolin’s ulcers develop from inflammation and ulcers on the leg.

In recent years, in addition to BIA-ALCL, implant-associated diffuse large B-cell lymphomas (DLBCL) have also been described, such as breast implant-associated EBV-positive diffuse large B-cell lymphoma [44, 45, 46, 47]. These are usually negative for ALK, CD2, CD3, and B-cell markers [48], but positive for CD20 [44, 47, 48, 49], CD5, BCL-2, CD21, CD23, IgD, IgM, [49]. EBV-positive diffuse large B-cell lymphomas are positive for CD20, CD30, CD79a, MUM1, and PAX-5 [44, 47, 48], and, similar to BIA-ALCL, are associated in most cases with textured implants [45, 47]. In one case, DLBCL was described after implantation of a smooth implant [50]. The prosthesis was often implanted well over 10 years prior [44, 45, 47, 48]. The FDA has documented fewer than 30 cases based on literature searches; 12 cases have been reported to date (as of: 8 September 2022) [51].

Similar to BIA-ALCL, chronic inflammation is also thought to play a major role in the pathogenesis of DLBCL [52].

However, Bacon and O’Donoghue argue that in some of the supposedly implant-associated lymphomas described [53, 54], a causal relationship between lymphoma and implant is unlikely, especially if it was found only very close to the implant [53] or on the abluminal surface [54] of the implant capsule [55]. In addition, some patients also had a systemic lymphoma. In contrast, they see a potential correlation with DLBCL (DLBCL-CI) which is associated with chronic inflammation, or fibrin-associated DLBCL (FA-DLBCL) [55].

Since DLBCL-CI/FA-DLBCL are associated with symptoms similar to BIA-ALCL and can therefore also be excluded in the presence of CD-30-positive large cell lymphoma [48], these diseases should also be excluded in the presence of late seroma. If suspected, EBER (EBV-encoded RNA) should be included in the immunohistochemical panel.

In terms of treatment, there is still no global consensus due to the rarity, but prompt en-bloc resection, as for BIA-ALCL [36], is recommended [49, 56]. As in cases of suspected BIA-ALCL, a
puncture and cytological examination of the markers mentioned above should also be performed in cases of periprosthetic seroma that occurred later than 6 months after surgery [49, 50].

Breast implant-associated squamous cell carcinoma (BIA-SCC)

Breast implant-associated squamous cell carcinoma (SCC) was described as early as 1994 [57]. To date, the FDA has documented 19 cases based on literature searches (as of: 8 March 2023) [51]. This extremely rare disease is associated with both textured and smooth implants [51, 58, 59, 60, 61]. A case of SCC following the injection of liquid silicone into the breast has also been documented [62]. Most cases describe the first prosthesis being implanted more than 10 years prior [57, 59, 60, 61, 63, 64, 65].

The origin of a squamous epithelium is unclear. Metaplasia of the capsule cells due to a chronic inflammatory stimulus is possible. However, abrasion implantation in the context of implant insertion or laceration of the gland ducts is also being discussed [57].

Similar to BIA-ALCL, implant-associated SCC is also associated with a late seroma; however, histopathologically, compared to BIA-ALCL, there is usually a circumscribed tumor in addition to the periprosthetic seroma [57, 58, 64]. Antibodies against cytokeratin should be included during the work-up.

Due to the very rare cases described to date, there is still no clear consensus on treatment. However, it is a highly aggressive tumor with rapid infiltration beyond the capsule, as well as poor prognosis. Rapid and radical treatment is therefore essential. Again, an en-bloc or R0 resection is recommended, which in some cases has been supplemented by adjuvant radiotherapy or radiochemotherapy [61, 64, 66]. Rapid progression with metastasis was described in three cases despite R0 resection with adjuvant radiotherapy or radiochemotherapy [61, 64]; in several cases, no follow-up information was provided [57, 60]. Only Palletta et al. described no local or systemic regression after one year of follow-up [65].

Conclusion

Breast implant-associated anaplastic large cell lymphoma (BIA-ALCL) is a rare complication that predominantly occurs with macrotextured breast implants. The pathogenesis is still largely unknown. Several theories with different approaches are being discussed, so there may be multiple factors at play. In all hypotheses, however, a chronic inflammatory response is the driving force.

Prognosis is very favorable if treatment is started early. However, since more advanced stages have a significantly less favorable course, a comprehensive preoperative risk assessment and patient information prior to implant insertion is essential, as well as ongoing follow-up care. The other tumors described in the context of breast implants are extremely rare. However, SCC has a much poorer prognosis and must be detected early and treated radically. The prophylactic removal of implants that are unremarkable both clinically and in imaging is not recommended.

Acknowledgement


Conflict of Interest

The authors declare that they have no conflict of interest.

References/Literatur


43. Schiller JF, Lowy DR. An Introduction to Virus Infections and Human Cancer. Recent Results Cancer Res 2021; 217: 1–11. doi:10.1007/978-3-030-57362-1_1


